Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

168.80SEK
23 Aug 2019
Change (% chg)

-1.20kr (-0.71%)
Prev Close
170.00kr
Open
170.00kr
Day's High
172.30kr
Day's Low
168.30kr
Volume
459,716
Avg. Vol
860,218
52-wk High
299.60kr
52-wk Low
160.50kr

Latest Key Developments (Source: Significant Developments)

AstraZeneca Agrees To Buy U.S. FDA Priority Review Voucher From SOBI
Thursday, 22 Aug 2019 02:10am EDT 

Aug 22 (Reuters) - Astrazeneca Plc ::AGREES TO BUY US FDA PRIORITY REVIEW VOUCHER FROM SOBI.ASTRAZENECA - HAS AGREED TO BUY A US FOOD AND DRUG ADMINISTRATION (FDA) PRIORITY REVIEW VOUCHER (PRV) FOR A TOTAL CASH CONSIDERATION OF $95M.ASTRAZENECA - TO BUY A US FOOD AND DRUG ADMINISTRATION (FDA) PRIORITY REVIEW VOUCHER (PRV) FROM A SUBSIDIARY OF SWEDISH ORPHAN BIOVITRUM AB.NO OPERATING PROFIT OR LOSS WAS ATTRIBUTABLE TO PRV IN PRIOR ACCOUNTING PERIODS AT SOBI..  Full Article

Swedish Orphan Biovitrum Completes Acquisition Of Emapalumab
Thursday, 18 Jul 2019 06:10am EDT 

July 18 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::SOBI COMPLETES ACQUISITION OF EMAPALUMAB AND RELATED ASSETS.ACQUISITION MEANS THAT PREVIOUSLY ANNOUNCED EXCLUSIVE LICENCE AGREEMENT WITH NOVIMMUNE WILL BE SUPERSEDED.ACQUISITION IS EXPECTED TO BE EARNINGS NEUTRAL IN 2019.  Full Article

Swedish Orphan Biovitrum Q2 EBITA Grows To SEK 1.04 Bln
Wednesday, 17 Jul 2019 02:00am EDT 

July 17 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::SOBI PUBLISHES REPORT FOR Q2 2019.Q2 TOTAL REVENUES SEK 3.16 BILLION VERSUS SEK 2.29 BILLION YEAR AGO.Q2 EBITA SEK 1.04 BILLION VERSUS SEK 951 MILLION YEAR AGO.FINANCIAL OUTLOOK 2019 - UPDATED.SOBI EXPECTS REVENUE FOR FULL YEAR TO BE IN RANGE OF SEK 13,000 - 13,500 M (12,500 - 13,000).EBITA FOR FULL YEAR IS EXPECTED TO BE IN RANGE OF SEK 5,300 - 5,500 M(1)(5,000 - 5,300)(2), EXCLUDING RESTRUCTURING COSTS.UPDATED OUTLOOK REFLECTS CONTINUED STRONG PRODUCT SALES IN HAEMOPHILIA AND PROMISING UPTAKE OF GAMIFANT IN US.  Full Article

Sobi Increases Investments In Late-Stage Development In Haematology And Immunology
Wednesday, 12 Jun 2019 07:10am EDT 

June 12 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::SOBI STRENGTHENS FOCUS AND INCREASES INVESTMENTS IN LATE-STAGE DEVELOPMENT IN HAEMATOLOGY AND IMMUNOLOGY.PLANS TO ESTABLISH CENTRES OF EXCELLENCE IN SWEDEN AND SWITZERLAND.NEW FOCUS OF RESEARCH AND DEVELOPMENT ORGANISATION WOULD LEAD TO ANNUAL SAVINGS OF SEK 200-300 M IN 2020 TO BE REALLOCATED TO LATE-STAGE DEVELOPMENT.COSTS OF AROUND SEK 100-200 M RELATING TO REORGANISATION AND REDUNDANCIES WILL BE CHARGED IN 2019..INTENDED REORGANISATION OF RESEARCH AND DEVELOPMENT TO INCREASE FOCUS AND INVESTMENT IN LATE-STAGE DEVELOPMENT.GUIDANCE FOR FULL YEAR 2019, EXCLUDING RESTRUCTURING COSTS, REMAINS UNCHANGED.SOBI ALSO INTENDS TO DISCONTINUE DISCOVERY/EARLY RESEARCH AND PARTNER RESEARCH AND DEVELOPMENT PROGRAMMES OUTSIDE ITS CORE FOCUS AREAS.INTENTION TO DIVEST SOBI006 PROJECT AND SOBI003 PROJECT..IN 2019 RESTRUCTURING COSTS OF AROUND SEK 100-200 M RELATING TO REORGANISATION AND REDUNDANCIES CORRESPONDING TO APPROXIMATELY 90 POSITIONS WILL BE CHARGED.  Full Article

SOBI Acquires Emapalumab And Related Assets
Wednesday, 12 Jun 2019 07:00am EDT 

June 12 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::SOBI ACQUIRES EMAPALUMAB AND RELATED ASSETS.ACQUISITION IS EXPECTED TO BE EARNINGS NEUTRAL IN 2019 AND COMPLETED DURING Q3 2019, SUBJECT TO CUSTOMARY CLOSING CONDITIONS..ACQUISITION MEANS THAT PREVIOUSLY ANNOUNCED EXCLUSIVE LICENCE AGREEMENT WITH NOVIMMUNE WILL BE SUPERSEDED..CONSIDERATION FOR ACQUISITION IS CHF 515 M (SEK 4,897 M).ACQUISITION IS DEBT-FINANCED.TO ACQUIRE, FROM NOVIMMUNE'S SHAREHOLDERS, A NEWLY ESTABLISHED COMPANY OWNING EMAPALUMAB AND RELATED ASSETS.  Full Article

FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis
Tuesday, 20 Nov 2018 09:40am EST 

Nov 20 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH).SWEDISH ORPHAN BIOVITRUM - GAMIFANT IS EXPECTED TO BE AVAILABLE FOR ADMINISTRATION IN TREATMENT CENTERS ACROSS U.S. IN Q1 OF 2019.  Full Article

AstraZeneca To Divest U.S. Synagis Rights To Swedish Orphan Biovitrum
Tuesday, 13 Nov 2018 02:01am EST 

Nov 13 (Reuters) - AstraZeneca PLC ::ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI.PROPOSED DEAL FOR UPFRONT CONSIDERATION OF $1.5BN PLUS FURTHER CONTINGENT PAYMENTS.TRANSACTION GRANTS SOBI RIGHT TO PARTICIPATE IN US PROFITS AND LOSSES FOR MEDI8897.SOBI WILL COMMERCIALISE SYNAGIS IN US AND AROUND 130 ASTRAZENECA EMPLOYEES WILL TRANSFER TO SOBI AS PART OF DEAL.WILL ALSO GET UP TO $470M IN SALES-RELATED PAYMENTS FOR SYNAGIS, $175M MILESTONE AFTER BLA SUBMISSION FOR MEDI8897.  Full Article

Sobi to buy Synagis U.S. rights from Astrazeneca, pays $1.5 bln upfront
Tuesday, 13 Nov 2018 02:00am EST 

Nov 13 (Reuters) - Swedish Orphan Biovitrum ::SOBI™ TO ACQUIRE SYNAGIS® US RIGHTS FROM ASTRAZENECA - CREATES A PLATFORM FOR GLOBAL GROWTH.SAYS ENTERED INTO AGREEMENTS TO ACQUIRE PERPETUAL RIGHTS TO SYNAGIS® (PALIVIZUMAB) IN US FROM ASTRAZENECA AND TO PARTICIPATE IN 50 PER CENT OF FUTURE EARNINGS OF CANDIDATE DRUG MEDI8897 IN US.SAYS TOTAL UPFRONT CONSIDERATION CORRESPONDS TO USD 1,500 M (SEK 13.6 B.SAYS PAYMENT CONSISTING OF USD 1,000 M (SEK 9.1 B) IN CASH AND USD 500 M (SEK 4.5 B) EQUIVALENT IN NEWLY ISSUED SOBI SHARES.SAYS FOLLOWING COMPLETION OF ACQUISITION, ASTRAZENECA WILL HOLD 8.1 PER CENT OF TOTAL SHARES AND VOTES IN SOBI.SAYS SIGNIFICANT TOP LINE ADDITION WILL GIVE SOBI SUBSTANTIAL RECURRING EARNINGS TO FURTHER ADVANCE US EXPANSION AND ENABLE FUTURE STRATEGIC ACQUISITIONS OVER MID-TERM, POSITIONING COMPANY WELL FOR ITS NEXT PHASE OF GROWTH.SAYS WILL ALSO PAY USD 20 M (SEK 181 M) IN CASH, PER YEAR, FOR THREE YEARS 2019-2021 AS CONSIDERATION FOR MEDI8897.SAYS MAY PAY UP TO USD 470 M (SEK 4.3 B) FOR SYNAGIS SALES-RELATED MILESTONES FROM 2026 ONWARDS, PLUS, USD 175 M (SEK 1.6 B) FOLLOWING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR MEDI8897.SAYS AGREEMENT ALSO INCLUDES POTENTIAL NET PAYMENTS OF APPROXIMATELY USD 110 M (SEK 1.0 B) ON ACHIEVEMENT OF OTHER MEDI8897 PROFIT AND DEVELOPMENT-RELATED MILESTONES.SAYS COMPLETION OF ACQUISITION IS SUBJECT TO CERTAIN CUSTOMARY CONDITIONS AND REGULATORY APPROVALS.  Full Article

Pharma Mar Signs Deal With Impilo Pharma For Yondelis
Friday, 27 Jul 2018 05:47am EDT 

July 27 (Reuters) - Pharma Mar Sa ::SIGNS DEAL WITH IMPILO PHARMA FOR EXCLUSIVE PROMOTION AND DISTRIBUTION OF YONDELIS IN NORDICS AND EASTERN EUROPE.SAYS WILL RECEIVE AN UP-FRONT PAYMENT OF 2 MILLION EUROS.AGREEMENT WILL REPLACE CURRENT AGREEMENT BETWEEN PHARMA MAR AND SWEDISH ORPHAN BIOVITRUM INTERNATIONAL.  Full Article

Sobi Q2 core profit beats expectations, raises forecast
Wednesday, 18 Jul 2018 02:00am EDT 

July 18 (Reuters) - Swedish Orphan Biovitrum AB ::Q2 TOTAL REVENUES OF SEK 2,289 M (1,639) FOR Q2.Q2 EBITA INCREASED BY 94 PER CENT TO SEK 951 MLN (492) FOR Q2.SAYS SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 8,600-8,800 M (7,900-8,100)..SAYS GROSS MARGIN IS EXPECTED TO BE AT LEAST 70 PER CENT (UNCHANGED).SAYS SOBI EXPECTS EBITA FOR FULL-YEAR TO BE IN RANGE OF SEK 3,400-3,600 M (2,800-3,000).REUTERS POLL: SOBI Q2 EBITA WAS SEEN AT 783 MILLION SEK, REVENUES AT 2,111 MILLION.  Full Article